Dose-Intense Temozolomide in Recurrent Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

November 30, 2011

Study Completion Date

October 31, 2013

Conditions
GlioblastomaGliosarcoma
Interventions
DRUG

Temozolomide

Taken orally daily for the first three weeks of a four-week cycle.

Trial Locations (6)

19104

University Of Pennsylvania, Philadelphia

27157

Wake Forest Univsersity, Winston-Salem

02111

Tufts Medical Center, Boston

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

03756

Dartmouth-Hitchcock Medical Center, Lebanon

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

University of Pennsylvania

OTHER

collaborator

Wake Forest University Health Sciences

OTHER

collaborator

Tufts Medical Center

OTHER

collaborator

Dartmouth-Hitchcock Medical Center

OTHER

collaborator

Schering-Plough

INDUSTRY

lead

Patrick Y. Wen, MD

OTHER